Polyrizon Ltd. 取得重大进展:其过敏阻断剂临床试验获中央机构审查委员会批准

美股速递
Jun 29

Polyrizon Ltd. 在研发道路上迈出了坚实的一步。公司已成功获得中央机构审查委员会对其过敏阻断剂临床试验的批准,这标志着其核心产品向市场推进的关键障碍已被扫清。此项进展不仅为后续研究的开展铺平了道路,也显著增强了市场对该疗法未来潜力的信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10